Neuroscience Day 2020 Event Resources

Enter the New Era of CNS Drug Discovery

Neuroscience Illustration of dopamine neuron.

Even in a pandemic, research never stops. Tapping into our global network and deep resources, Charles River is leading the charge into a new era of neuroscience discovery with a one-of-a-kind virtual event. Neuroscience Day 2020 brought you the opportunity to connect with the research community and keep your programs going strong with the insight, data, and tools you’ll discover during a day full of presentations, breakouts, and networking. Browse our presentations from Neuroscience Day 2020 below.

Neurological Biomarkers to Study Mechanisms of Disease and Potential Therapies

 

Targeting Soluble TNF-dependent Chronic Inflammation to Reduce Risk of Age-related Neurodegenerative Diseases | Malu Tansey, PhD, Center for Translational Research in Neurodegenerative Research & University of Florida

 

 


Translational Biomarkers in Neuroscience Research | Julien Roeser, PhD, Charles River


Diffusion MRI to Quantify White Matter Microstructure and Assess Neuroinflammation, Demyelination and Axonal Loss | Maxime Descoteaux, PhD, CSO Imeka & University of Sherbrooke

Utilizing Cellular & Gene Therapies to Treat Neurological Disorders

 

Engrafting iPSC-Derived Dopamine Neurons as a Therapeutic Strategy for Parkinson's Disease | Howard Federoff, MD, PhD, Aspen Neuroscience


Stem Cell-Derived Striatal Neurons to Study Huntington’s Disease | Mariangela Iovino, PhD, Group Leader, Integrated Biology Charles River


Screening in iPSC-Derived Neurons for Modifiers of Alzheimer's-Related Phenotypes | Shushant Jain, PhD, Group Leader, Discovery, Charles River


Gene Therapy for Huntington's Disease - Non-Clinical Path to Clinical Application | Lisa Spronck, MSc, ERT, uniQure


Towards Optogenetic Cochlea Implants | Marcus Jeschke, PhD, Auditory Neuroscience and Optogenetics Laboratory, German Primate Center, Göttingen

Safety Assessment Considerations When Developing CNS Drugs

 

An Overview of the Main CNS Safety Liabilities in Drug Development | Annie Delaunois, PhD, UCB Pharma Team


Neurological Assays, from Neuronal Network Excitability to Synaptic Channel Activity | Lois Miraucourt, PhD, Charles River


Using the Proportionater Counting Method to Assess Neuronal Loss Among Susceptible Cell Populations in Substantia Nigra Pars Compacta of MPTP Treated Mice | Michael Staup, PhD, Charles River